[go: up one dir, main page]

UY32466A - Sal de sodio de acido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino benzoico como inhibidor de dhodh - Google Patents

Sal de sodio de acido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino benzoico como inhibidor de dhodh

Info

Publication number
UY32466A
UY32466A UY0001032466A UY32466A UY32466A UY 32466 A UY32466 A UY 32466A UY 0001032466 A UY0001032466 A UY 0001032466A UY 32466 A UY32466 A UY 32466A UY 32466 A UY32466 A UY 32466A
Authority
UY
Uruguay
Prior art keywords
difluorophenyl
sodium salt
ciclopropil
pirimidin
acid
Prior art date
Application number
UY0001032466A
Other languages
English (en)
Inventor
Garcia Gonzalez Nuria
Serra Masia Xavier
Francesc Carrera Carrera
Montserrat Julia Jane
Debethune Laurent
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40903239&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32466(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of UY32466A publication Critical patent/UY32466A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a la sal de sodio cristalina hidrosoluble de ácido 2-{[5-ciclopropil-2-{[2-(2,6`-difluorofenil)pirimidin-5-il]amino benzoico y a sus solvatos farmacéuticamente aceptables.
UY0001032466A 2009-03-13 2010-02-24 Sal de sodio de acido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino benzoico como inhibidor de dhodh UY32466A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09382033A EP2239256A1 (en) 2009-03-13 2009-03-13 Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor

Publications (1)

Publication Number Publication Date
UY32466A true UY32466A (es) 2010-09-30

Family

ID=40903239

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032466A UY32466A (es) 2009-03-13 2010-02-24 Sal de sodio de acido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino benzoico como inhibidor de dhodh

Country Status (22)

Country Link
US (1) US8501943B2 (es)
EP (2) EP2239256A1 (es)
JP (1) JP2012520250A (es)
KR (1) KR20110125653A (es)
CN (1) CN102348687B (es)
AR (1) AR075736A1 (es)
AU (1) AU2010223526A1 (es)
CA (1) CA2754801A1 (es)
CL (1) CL2011002215A1 (es)
CO (1) CO6420336A2 (es)
EA (1) EA020218B1 (es)
EC (1) ECSP11011383A (es)
IL (1) IL214518A0 (es)
MX (1) MX2011009148A (es)
NZ (1) NZ594492A (es)
PE (1) PE20120114A1 (es)
SG (1) SG173825A1 (es)
TW (1) TW201032811A (es)
UA (1) UA105788C2 (es)
UY (1) UY32466A (es)
WO (1) WO2010102824A2 (es)
ZA (1) ZA201105742B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
RU2586212C2 (ru) 2008-12-08 2016-06-10 Мандифарма Интернэшнл Корпорейшн Лимитед Композиции ингибиторов тирозинкиназных рецепторов белков
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid
EP2444088A1 (en) * 2010-10-22 2012-04-25 Almirall, S.A. Amino derivatives for the treatment of proliferative skin disorders
US20120195933A1 (en) * 2011-01-27 2012-08-02 Ralph Stefan Pharmaceutical compositions comprising tasocitinib
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
MX2017003439A (es) 2014-09-17 2017-12-04 Mundipharma International Corporation Ltd Formas cristalinas de inhibidores de tirosina cinasa y sus sales.
WO2018136009A1 (en) 2017-01-20 2018-07-26 Aslan Pharmaceuticals Pte Ltd Combination therapy
CN114957650B (zh) * 2022-06-11 2024-05-10 新疆腾域鸿源农业科技有限公司 一种聚天冬氨酸钾的制备方法及其在植物生长促进剂中的应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE209518T1 (de) 1995-06-21 2001-12-15 Asta Medica Ag Arzneipulverkartusche mit integrierter dosiereinrichtung, sowie pulverinhalator
DE19547648A1 (de) 1995-12-20 1997-06-26 Hoechst Ag Zubereitung, enthaltend High Density Lipoproteine und Crotonsäureamidderivate
DE19610955A1 (de) 1996-03-20 1997-09-25 Hoechst Ag Kombinationspräparat, enthaltend 5-Methylisoxazol-4-carbonsäure-(4-trifluormethyl)- anilid und N-(4-Trifluormethylphenyl)-2-cyan-3- hydroxycrotonsäureamid
GB9804343D0 (en) 1998-02-27 1998-04-22 Univ Cardiff Chemical compounds
SK17632001A3 (sk) 1999-06-10 2003-03-04 Warner-Lambert Company Liečivo na liečbu Alzheimerovej choroby, inhibíciu agregácie amyloidového proteínu a spôsob na zobrazenie depozít amyloidu
PT1381356E (pt) 2001-04-05 2008-07-24 Aventis Pharma Inc Utilização de (4' -trifluorometilfenil) - amida do ácido (z) -2- ciano-3-hidroxi-but-2-enóico para tratamento da esclerose múltipla
PE20030120A1 (es) 2001-06-19 2003-02-12 Merck & Co Inc Sal amina de un antagonista de receptor de integrin
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
PE20040844A1 (es) 2002-11-26 2004-12-30 Novartis Ag Acidos fenilaceticos y derivados como inhibidores de la cox-2
US7071355B2 (en) 2002-12-23 2006-07-04 4 Sc Ag Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056747A1 (en) 2002-12-23 2004-07-08 4Sc Ag Dhodh-inhibitors and method for their identification
SE0400234D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New compounds, methods for their preparation and use thereof
BRPI0511290A (pt) 2004-05-21 2007-12-18 Uab Research Foundation composições e métodos referentes aos inibidores da sìntese da pirimidina
WO2006022442A1 (ja) 2004-08-24 2006-03-02 Santen Pharmaceutical Co., Ltd. ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体
WO2006044741A1 (en) 2004-10-19 2006-04-27 Aventis Pharmaceuticals Inc. Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease
ES2265276B1 (es) 2005-05-20 2008-02-01 Laboratorios Almirall S.A. Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
ES2303758B1 (es) 2006-02-20 2009-08-13 Laboratorios Almirall S.A. Nuevos derivados de piridin-3-amina.
ES2301380B1 (es) 2006-08-09 2009-06-08 Laboratorios Almirall S.A. Nuevos derivados de 1,7-naftiridina.
ES2319596B1 (es) 2006-12-22 2010-02-08 Laboratorios Almirall S.A. Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico.
NZ579040A (en) 2007-02-06 2011-01-28 Chelsea Therapeutics Inc New compounds, methods for their preparation and use thereof
UY31272A1 (es) 2007-08-10 2009-01-30 Almirall Lab Nuevos derivados de ácido azabifenilaminobenzoico
EP2135610A1 (en) 2008-06-20 2009-12-23 Laboratorios Almirall, S.A. Combination comprising DHODH inhibitors and methotrexate
EP2210615A1 (en) 2009-01-21 2010-07-28 Almirall, S.A. Combinations comprising methotrexate and DHODH inhibitors
EP2228367A1 (en) 2009-03-13 2010-09-15 Almirall, S.A. Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors
EP2230232A1 (en) 2009-03-13 2010-09-22 Almirall, S.A. Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
EP2314577A1 (en) 2009-10-16 2011-04-27 Almirall, S.A. Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid

Also Published As

Publication number Publication date
PE20120114A1 (es) 2012-02-20
MX2011009148A (es) 2011-09-28
EP2406221A2 (en) 2012-01-18
US8501943B2 (en) 2013-08-06
IL214518A0 (en) 2011-09-27
JP2012520250A (ja) 2012-09-06
US20120003184A1 (en) 2012-01-05
WO2010102824A2 (en) 2010-09-16
KR20110125653A (ko) 2011-11-21
CA2754801A1 (en) 2010-09-16
EP2239256A1 (en) 2010-10-13
CL2011002215A1 (es) 2012-03-09
EA020218B1 (ru) 2014-09-30
CO6420336A2 (es) 2012-04-16
CN102348687A (zh) 2012-02-08
TW201032811A (en) 2010-09-16
WO2010102824A3 (en) 2010-11-18
UA105788C2 (uk) 2014-06-25
ECSP11011383A (es) 2011-11-30
NZ594492A (en) 2013-11-29
EA201101301A1 (ru) 2012-04-30
AU2010223526A1 (en) 2011-08-25
SG173825A1 (en) 2011-09-29
AR075736A1 (es) 2011-04-20
CN102348687B (zh) 2014-04-02
ZA201105742B (en) 2012-04-25

Similar Documents

Publication Publication Date Title
UY32466A (es) Sal de sodio de acido 5-ciclopropil-2-{[2-(2,6-difluorofenil)pirimidin-5-il]amino benzoico como inhibidor de dhodh
AR117799A2 (es) Sal(es) de dimetil-amida del ácido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]-pirimidin-6-carboxílico y procesos para su elaboración
AR114946A2 (es) Formas cristalinas de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
CR20130023A (es) Pirazolo[1,5-a]pirimidinas para tratamiento antiviral
CR20130470A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA
EP2726075A4 (en) NEW CRYSTALLINE FORMS OF A DIPEPTIDYL-PEPTIDASE IV HEMMER
CR20110370A (es) Derivados de sulfonamida
EP2484359A4 (en) HEPARANASEAKTIVITÄTSHEMMER
PL2421372T3 (pl) Wysoko stężone kompozycje chwastobójcze soli glifosatu i 2,4-D
PH12015501649A1 (en) Sodium salt of 6-fluoro-3-hydroxy-2-pyrazine carboxamide
EA201201378A1 (ru) Определенные аминопиримидины, композиции на их основе и способы их использования
HN2007000407A (es) Compuesto de biaril eter urea
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
BRPI1012638B8 (pt) métodos e intermediários para preparar agentes farmacêuticos
CR20130419A (es) Derivados heterocíclicos de amina
PA8855501A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
ECSP099565A (es) Compuesto de 2-amino pirimidina
PH12014502210A1 (en) Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl]ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one
UY32405A (es) Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapia
WO2011058524A3 (en) Crystalline forms of bosentan salts and processes for their preparation
GT200900215A (es) Nuevo procedimiento de obtencion de la forma cristalina v de la agomelatina.
CL2013000578A1 (es) Sal cristalina de sodio del acido (e)-3-[2-(1-{[2-(5-bromo-pririmidin-2-il)-3-ciclopentil-1-metil-1h-indol-6-carbonil]-amino}-ciclobutil)-3-metil-3h-bencimidazol-5-il]-acrilico: sal amorfa;compuestos intermediarios; procedimientos de preparacion; composicion farmaceutica.
TH133899A (th) เกลือโซเดียมของกรด 5-ไซโคลโพรพิล-2-{[2-(2,6-ไดฟลูออโรฟีนิล)ไพริมิดิน-5-อิล]อะมิโน}เบนโซอิค ในฐานะเป็นสารยับยั้ง dhodh
HK1161588A (en) Sodium salt of 5-cyclopropyl-2-{ü2-(2,6- difluorophenyl)pyrimidin-5-yl¨amino}benzoic acid as dhodh inhibitor
EA201290051A1 (ru) Кристаллическая форма i соли розувастатина цинка